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Abstract
Platelet-rich plasma (PRP) has received increasing interest in applied medicine, being widely used in clinical practice with
the aim of stimulating tissue healing. Despite the reported clinical success, there is still a lack of knowledge when
considering the biological mechanisms at the base of the activity of PRP during the process of muscle healing. The aim of
the present study was to verify whether the local delivery of PRP modulates specific molecular events involved in the early
stages of the muscle regeneration process. The right flexor sublimis muscle of anesthetized Wistar rats was mechanically
injured and either treated with PRP or received no treatment. At day 2 and 5 after surgery, the animals were sacrificed and
the muscle samples evaluated at molecular levels. PRP treatment increased significantly the mRNA level of the pro-
inflammatory cytokines IL-1b, and TGF-b1. This phenomenon induced an increased expression at mRNA and/or protein
levels of several myogenic regulatory factors such as MyoD1, Myf5 and Pax7, as well as the muscular isoform of insulin-like
growth factor1 (IGF-1Eb). No effect was detected with respect to VEGF-A expression. In addition, PRP application modulated
the expression of miR-133a together with its known target serum response factor (SRF); increased the phosphorylation of
aB-cristallin, with a significant improvement in several apoptotic parameters (NF-kB-p65 and caspase 3), indexes of
augmented cell survival. The results of the present study indicates that the effect of PRP in skeletal muscle injury repair is
due both to the modulation of the molecular mediators of the inflammatory and myogenic pathways, and to the control of
secondary pathways such as those regulated by myomiRNAs and heat shock proteins, which contribute to proper and
effective tissue regeneration.
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Introduction
Musculoskeletal injures are the most common cause of severe
long-term pain and physical disability, affecting hundreds of
millions of people around the world and accounting for the
majority of all sport-related injured [1]. In addition to health care
expenditures, the social cost of these injuries includes lost job
wages and production. In competitive or professional athletes, this
loss may have extreme consequences.
During the last decade, the rapidly increasing understanding of
the contribution of growth factors (GFs) in the healing of injured
tissue has given rise to a great interest in the use of autologous
platelet-rich plasma (PRP) as a new therapeutic tool in the field of
dentistry, dermatology, plastic and maxillofacial surgery, acute
trauma, chronic tendinopathies, cosmetic surgery, veterinary
medicine, and in muscle strain injuries [2–8].
Autologous PRP is obtained from the separation of whole blood
into plasma and red cell constituents, with the subsequent
concentration of platelets into a small volume of plasma.
Separation is frequently achieved by varying degrees of centrifu-
gation but may equally occur via cell separator apparatus [9]. PRP
is an example of autologous biomaterial product applied and
studied since the 1980s [10–12].
The rationale for the widespread use of PRP resides in the fact
that it is a simple, efficient, and minimally invasive method of
obtaining a natural concentration of autologous GFs, which may
modulate and regulate the tissue-healing process at a cellular level
[13]. The rationale is that by the delivery of various GFs and
cytokines from the a–granules contained in platelets, PRP
enhances the recruitment, proliferation, and differentiation of
cells involved in tissue regeneration.
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Although there are several basic science studies, animal studies,
and small case reports regarding PRP-related products, there are
only a few controlled, clinical studies providing a high level of
medical evidence when considering the potential benefits of PRP
[2–8]. The number of participants in studies is typically small and
the majority of studies are underpowered. Moreover, the studies
examining the PRP effect have not used standardized techniques
and the majority are anecdotal studies based on small case series.
This is particularly evident when considering the treatment of
musculoskeletal injuries, a field in which some interesting
promising findings have been obtained, but most results are still
preliminary and controversial.
Given the importance of an accelerated muscle regeneration,
especially within the initial week of the muscle repair process
where the inflammation and the regeneration phase take place, it
is clear that further studies are required in order to recommend or
discourage the adoption of this approach in routine clinical
practice. Moreover, the biological mechanisms for the improved
muscle recovery resulting from the use of PRP after injury need to
be elucidated.
In the present study, we used our established and reproducible
animal model to test the effects of autologous PRP on the
molecular processes that characterize the early stages of muscle
regeneration. On the basis of previous results [7,14], we
hypothesized that the local delivery of PRP into injured skeletal
muscle accelerates specific processes such as the control of
inflammatory reaction as well as myogenesis.
Since myoblast proliferation following myotrauma is orches-
trated by multiple factors including growth factors, transcription
factors, and miRNAs relating to myogenesis in vivo, in this study
we analyzed at 2- and 5-day post-injury the multi-directionally
effects of PRP on the expression of several cytokines (TNFa, IL-6,
IL-10, IL-1b, and TGF-1b), myogenic response factors (MRFs)
(MyoD1, Myf5, Pax7, Myogenin, and Mrf4), GFs (VEGF-A and
IGF-1Eb), as well as myo-miRNAs (miR-1, miR-133a, and miR-
206), stress-response proteins (Hsp70, Hsp27 and aB-crystallin)
and apoptotic markers (NF-kB-p65, Bcl-2, Bax, and caspase 3).
Materials and Methods
Ethics Statement
All procedures were supervised by a veterinarian and approved
by the Committee on the Ethics of Animal Experiments of the
University of Turin in accordance with the European Commu-
nities Council Directive of 24 November 1986 (86/609/EEC).
All surgery was performed under sodium pentobarbital anes-
thesia, and all efforts were made to minimize animal suffering.
Animals and surgery
Wistar male adult rats (n = 50), weighing approximately 250g
each, were used. All animals were kept in a cage in a room with
controlled temperature and humidity, with a light/dark cycle of
12/12 hours, and allowed food and water ad libitum. Animals
were operated under general anesthesia by intramuscular injection
of tiletamine + zolazepam (Zoletil) 3 mg/kg. The surgical
procedures were performed with the aid of a surgical microscope
(Zeiss OPMI7, Jena, Germany). A longitudinal incision was
performed on the right anterior limb from the elbow region to the
wrist in order to access the flexor sublimis muscles of the upper
joint of the digits. The muscle was then injured transversely and
medially using a scalpel. The wedge-shaped lesion was 3 mm long,
2 mm wide and 3 mm deep (see panel D in Figure S1).
To evaluate a possible effect of PRP on muscle regeneration
process, an injury was made to the right flexor muscles of 20 rats
and immediately treated with PRP (PRP group), 20 rats were
subjected to the same muscle injury and left untreated (NO-PRP
group), 10 rats, used as controls, were left uninjured (Ctrl group).
After recovery from anesthesia, animals returned free in their
cages. They were sacrificed at day 2 and 5 post-surgery and all
muscle samples were immediately either frozen in liquid nitrogen
and stored at 280uC until analyses were performed (protein and
RNA analysis) or processed for immunohistochemistry.
Blood collection and preparation of platelet-rich plasma
Blood was collected by intracardiac puncture of the anesthetized
rats immediately before the surgical injury to the muscle (see panel
A in Figure S1). Briefly, a needle (21G) was inserted at the base of
the sternum at a 20u angle just lateral of the midline. The
intracardiac blood (3–3.5 mL) was slowly withdrawn into a syringe
containing 1 mL of 3.8% sodium citrate. Blood was then
transferred into sterile tubes containing sodium citrate and
underwent a first centrifugation at 220 g for 15 minutes (see
panel B in Figure S1). To objectively determine the number of
platelets and investigate the presence of other blood cells, a
complete blood count was performed using a cell counter ADVIA
2021 (Bayer, Leverkusen, Germany) on a small amount of the
plasma layer obtained after the first centrifugation (the white blood
cell content was always very low: (0.01 6 0.082)6103/mm3, P-
PRP subtype [9]. A second centrifugation at 1,270 g for 5 minutes
allowed the platelets to fall to the bottom of the tube. The pellet
was re-suspended in 100 mL of plasma (baseline range: 500–1300
6103 platelet/mL; the platelet concentration was always at least
four times greater than the initial value, 2–5.26106 platelet/mL).
In agreement with the PAW (Platelet, Activation, and White cells)
classification system of PRP, we can codify our preparation as P4-
x-Bb (Platelet concentration .1,250,000 = P4; exogenous = x,
Total White Blood Cells # baseline = B; Neutrophils # base-
line = b) [15]. This platelet enriched preparation was activated
with 20 mL of 10% calcium chloride (Braun, Melsungen,
Germany, 1,000 IE/mL CaCl2-2SG) at 37uC and, after jellifica-
tion, immediately inserted using tweezers into the injured muscle
of the same animals from which the blood had been drawn (see
panel C-H in Figure S1). The wound was then sutured and washed
with saline solution.
RNA extraction and real-time PCR analysis
Total RNA was obtained from regenerated tissue at day 2 and 5
(half muscle, n = 5 in each group) using TRIZOL (Invitrogen)
according to the manufacturer’s procedure.
Real-time quantitative RT-PCR was performed on a 7500 Real
Time PCR System (Applied Biosystems, Life Technologies). Each
20 mL reaction mixture contained 10 mL of Power SYBR Green
RNA-toCt 1stepMaster mix (26) (Life Technologies), 10p mol of
specific primer sets (see Table 1), 0.16 mL RT Enzyme Mix (1256)
(Life Technologies), 10–15 ng of RNA samples. The RT-PCR
amplification profile was as follows: RT step at 48uC for 30
minutes, followed by enzyme activation at 95uC for 10 minutes,
and then 40 cycles of denaturation at 95uC for 15 seconds and
annealing/extension at 60uC for 1 minute.
All samples were run in triplicate. Values obtained for each
target gene were compared with values of two internal control
genes (GAPDH, and b-actin). Since the values obtained were
similar, the normalization was arbitrarily done utilizing GAPDH
for all target genes. A threshold cycle (CT) was observed in the
exponential phase of amplification, and quantification of relative
expression levels was performed with standard curves for target
genes and the endogenous control. Geometric means were used
to calculate the DDCT (delta-delta CT) values and expressed as
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2-DDCT. The value of each control sample was set at 1 and was
used to calculate the fold-change of target genes.
Analysis of microRNA expression
Quantitative analysis of miR-1, 133 and 206 was performed by
RNA retro-transcription and subsequent TaqMan real-time PCR,
using a 7500 Real-Time PCR System as recommended by the
supplier (Applied Biosystems, Life Technologies). For each retro-
transcription reaction was used 20 ng of total RNA extracted from
each tissue sample.
Results were expressed as a cycle threshold (CT) value.
Normalized CT values were obtained by subtracting the CT
value of a small noncoding RNA control gene (RNU6B) from the
raw CT value of each analysedmiRNA. The value of each control
sample was set at 1 and used to calculate the fold-change of target
genes.
Immunofluorescent staining analysis
Muscles (n = 5 in each group) were fixed in 4% paraformalde-
hyde for 2–4 hours and then washed in phosphate-buffered saline.
Samples were dehydrated in an ascending series of graded alcohol,
cleared in xylene and embedded in paraffin. Series of transverse
sections of the muscles were obtained using a microtome RM2135
(Leica Microsystems, Wetzlar, Germany).
Before staining protocol, the slides were deparaffinized and
rehydrated with decreasing concentrations of alcohol. The sections
were subjected to the antigen retrieval, then permeabilised with
0.2% Triton X-100 and blocked in 3% BSA for 1 hour at room
temperature. Primary antiboby diluted in PBS with 1% BSA was
applied on sections for 1 hour at room temperature. Secondary
antibody diluted in PBS with 1% BSA was applied to the slides for
1 hour at room temperature in the dark to avoid photo-bleaching.
Slides were washed in PBS and subjected to staining of nuclei with
Hoechst and, then mounted. To evaluate muscle regeneration,
immunohistochemistry was performed with the following antibod-
ies: Laminin (Santa Cruz Biotechnology), MyoD1 (Santa Cruz
Biotechnology) and Pax7 (Santa Cruz Biotechnology). Secondary
Table 1. Rat-specific primer pair sequence for real-time PCR.
Gene Primer pair sequence base pair
(NCBI Reference Sequence)
MyoD1 F: GCGACACGCGATGACTTCTAT 73
(NM_176079.1) R: GGTCCAGGTCCTCAAAAAAGC
Pax7 F: GCCCTCAGTGAGTTCGATTAGC 70
(NM_001191984.1) R: TCCTTCCTCATCGTCCTCTTTC
Myf5 F: GGCTGGTCACTGCCTCATGT 70
(NM_001106783.1) R: CTTGCGTCGATCCATGGTAGT
Myogenin F: GACCCTACAGGTGCCCACAA 70
(NM_017115.2) R: ACATATCCTCCACCGTGATGCT
Mrf4 (myf6) F: GCCCCTTTCCGCCTAATC 71
(NM_013172.1) R: ACTAAGTCTCTTGCCTTTCATAAATTCTG
VEGF-A 55
Variant 1 (NM_031836.2) F: TACCTCCACCATGCCAAGTG
Variant 2 (NM_001110333.1) R: TCTGCTCCCCTTCTGTCGTG
Variant 3 (NM_001110334.1)
TGF-b1 F: CCACGTGGAAATCAATGGGA 91
(NM_021578.2) R: GGCCATGAGGAGCAGGAAG
IGF-1Eb F: GGAGGCTGGAGATGTACTGTGCT 138
(NM_001082478) R: TCCTTTGCAGCTTCCTTTTCTTG
TNFa F: AACACACGAGACGCTGAAGT 93
(NM_012675) R: TCCAGTGAGTTCCGAAAGCC
IL-6 F: GCAAGAGACTTCCAGCCAGT 88
(NM_012589.1) R: AGTCTCCTCTCCGGACTTGT
IL-1b F: TGACTTCACCATGGAACCCG 66
(NM_031512) R: TCCTGGGGAAGGCATTAGGA
IL-10 F: AAGGGTTACTTGGGTTGCCA 67
(NM_012854.2) R: GGGGCATCACTTCTACCAGG
b-actin F: GATCATTGCTCCTCCTGAGCG 92
(NM_031144.3) R: TGCTGATCCACATCTGCTGGA
GAPDH F: ATCACTGCCACCCAGAAGAC 90
(NM_017008.4) R: GGATGCAGGGATGATGTTCT
doi:10.1371/journal.pone.0102993.t001
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antibodies used for each immunostaining were as follows: Alexa
Fluor 488 donkey anti-goatIgG (H+L) (Molecular Probes) for Pax7
and MyoD and Alexa Fluor 546 goat anti-rabbit IgG (H+L)
(Molecular Probes) for laminin. A blue fluorescent dyes as Hoechst
33258 was applied for 15 minutes for nuclear staining.
Protein Isolation and Immunoblot Analyses
Rat’s skeletal muscles of each group (n = 5; half muscle, 100–
200 mg) at 2- and 5-day post-injury were lysed with the
appropriate buffer plus a mixture of protease and phosphatase
inhibitors (Sigma Aldrich). Homogenates were all centrifuged at
14,000 g for 15 min at 4uC. Equal amounts of muscle proteins
(15–20 mg) were separated by SDS-PAGE and transferred onto
PVDF membranes (Amersham Pharmacia Biotech). Membranes
were incubated overnight with the following primary antibodies:
MyoD1 (1: 2,000), SRF (1: 500), myogenin (1: 2,000), phospho-
ERK1/2 (1: 1,000), Hsp27 (1: 2,000), Bax (1:1,000) and Akt (Santa
Cruz) (Santa Cruz Biotechnology); phospho-p38MAPK (1: 1,000),
p38 (1: 1,000), caspase 3 (1: 1,000), phospho-NF-kB p65 (Ser536)
(1: 1,000), Bcl-2 (1: 1,000), phospho-Akt (Ser473) (1: 1,000),
phospho-HSP27 (Ser82) (1: 1,000) and p42 MAP Kinase (1: 1,000)
(ERK2) (Cell Signaling); Hsp70/72 (1:1,000), aB-crystallin (1:
2,000) and S59 phospho-aB-crystallin (1: 2,000) (Enzo Life
Science); GAPDH (1: 3,000) (Millipore). Blots were incubated
with the appropriate horseradish peroxidase-conjugated secondary
antibodies (1: 15,000) (Millipore), and proteins were visualized by
chemiluminescence (EuroClone). Bands were quantified by Image
J software. The expression of GAPDH was used as a normalizing
control. Phosphorylated isoform was normalized on the amount of
its total protein.
Statistical analysis
All values were expressed as means 6 SEM. Statistical analysis
was performed by a two-way ANOVA and subsequent Bonferro-
ni’s least significant difference test. p values less than 0.05 were
considered as statistically significant. All calculations were
performed using the GraphPad Prism 5 software.
Results
Gene expression analysis of intrinsic factors in
regenerating skeletal muscle of rat treated with or
without PRP
Real time PCR analysis revealed that mRNA transcripts for
cytokines, MRFs and GFs were differently modulated from the
presence of PRP (Figure 1).
As expected, at both experimental post-injury points there was
an increase in the transcriptional levels of TNFa, IL-6 and IL-10
mRNA in the injured muscles when compared with control (p,
0.05), without differences between groups treated or not with PRP
(p.0.05) (Figure 1A).
The mRNA expression of IL-1b, was elevated at day 2 in all
injured muscles (p,0.05), with a significantly higher transcript
level in the muscle treated with PRP when compared with those
left untreated (2d PRP vs. 2d NO-PRP 6.036 0.77 vs. 3.66 0.63,
p,0.05). At day 5, the IL-1b mRNA level returned to
approximately the same value of the Ctrl group, independently
from the presence of PRP (Figure 1A).
Yet, real-time PCR analysis revealed that TGF-1b was up-
regulated in injured muscles at each observation point, however,
the presence of PRP makes this increase more significant even in
comparison with the NO-PRP group (2d PRP vs. 2d NO-PRP 8.9
6 0.8vs.4.5 6 0.8, p,0.05; 5d PRP vs. 5d NO-PRP, 23.9 6 2.2
vs.5.1 6 0.3, p,0.05) (Figure 1A).
To further investigate myogenesis, we performed real-time PCR
for several MRFs such as MyoD1, Pax7, Myf5, Myogenin and
Mrf4 (Figure 1B). mRNA expression analysis showed that
MyoD1, one of the earliest markers of myogenic activation and
differentiation, was up-regulated at 2-day post-injury in both PRP
(4-fold increase respect to the Ctrl group) and NO-PRP (3-fold
increase in comparison with the Ctrl group), with a significant
enhancing effect of PRP (2d PRP vs. 2d NO-PRP, 3.80 6 0.01 vs.
2.59 6 0.28, p,0.05). After 5 days, MyoD1 level returned to
approximately the same level of the Ctrl group either in presence
or not of PRP (5d PRP vs. 5d NO-PRP 1.33 6 0.36 vs. 1.3 6
0.34, p.0.05). Although in a different manner, even the
expression of Myf5 and Pax7 were modulated by the presence
of PRP. Myf5 mRNA was significantly up-regulated at day 5 only
in injured muscle treated with PRP (5d PRP vs. NO-PRP, 2.49 6
0.67 vs. 0.85 6 0.12, p,0.05), while Pax7 was up-regulated at 5-
day post-injury in both experimental groups, however its
expression was significantly higher in PRP group when compared
to the NO-PRP group (5d PRP vs. NO-PRP, 5.11 6 0.24 vs. 2.68
6 0.13, p,0.05). The expression level of Myogenin mRNA, a
transcription factor important in the fusion and maturation of new
muscle fibres, was increased in all injured-groups and at both
sample timings, independently from PRP treatment (2d PRP 6.75
6 1.44; 2d NO-PRP 7.18 6 1.85; 5d PRP 7.69 6 2.18; 5d NO-
PRP 4.80 6 0.74, p,0.05). No differences were detected in the
expression level of Mrf4 mRNA among all groups analyzed (p.
0.05).
The analysis of the expression of GFs involved in muscle injury
such as VEGF-A and IGF-1Eb, showed that the mRNA level of
VEGF-A was unchanged in all muscle-injured groups, indepen-
dently from the presence of PRP (p.0.05) (Figure 1C). Otherwise,
the level of IGF-1Eb resulted up-regulated in all experimental
groups in comparison with Ctrls, with a specific enhancing effect
of PRP both at day 2 (2d PRP vs. 2d NO-PRP, 8.34 6 1.50 vs.
4.65 6 0.71, p,0.05), and more specifically at day 5 (5d PRP vs.
5d NO-PRP, 22.20 6 4.33 vs. 5.89 6 1.46, p,0.05), where the
IGF-1Eb mRNA expression in injured muscle tissues treated with
PRP resulted 4 times higher than in not treated injured muscles
(Figure 1C).
Protein expression of MyoD1, Pax7 and Myogenin in
injured muscle treated with PRP
Following muscle injury, MyoD1 protein was up-regulated
either in presence or in absence of PRP when compared to
uninjured muscle (p,0.05) However, at each point investigated (at
day 2 and 5), the levels of MyoD1 protein were higher in PRP with
respect to NO-PRP groups (2d PRP vs. NO-PRP group, 1.35 6
0.09 vs. 1.02 6 0.08; 5d PRP vs. NO-PRP group, 1.62 6 0.09 vs.
1.18 6 0.13, p,0.05) (Figure 2A). A different behavior was
observed when analyzing the modulation of Myogenin protein:
although there was a tendency to increase at day 2 after muscle
injury (Ctrl vs. PRP vs. NO-PRP group, 0.38 6 0.07 vs. 0.75 6
0.38 vs. 0.99 6 0.54, p.0.05), a significant induction could be
detected only at day 5 in presence of PRP (Ctrl vs. PRP group,
0.38 6 0.07 vs. 1.79 6 0.36, p,0.05) (Figure 2B).
The enhancing effect of PRP on MyoD1 and Pax7 was also
verified through immunohistochemical analysis. Figure 3 shows
the modification in the population of MyoD1- and Pax7-positive
nuclei relative to the total myonuclei during the regenerating
process of injured skeletal muscle at day 2 and 5, respectively. The
number of MyoD1-positive nuclei was significantly increased
when compared to the NO-PRP group already at 2-day post-
treatment (% of MyoD1-positive nuclei: PRP vs. NO-PRP group,
57 6 3 vs. 39 6 2, p,0.05), remaining significantly more
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expressed even at day 5 (% of MyoD1-positive nuclei: PRP vs.
NO-PRP group, 60 6 4.5 vs. 42 6 5, p,0.05)(Figure 3A-B). In
accord with the qRT-PCR analysis, the effect of PRP on the
number of Pax7-positive nuclei was observed only at 5-day post-
injury (% of Pax7-positive nuclei: PRP vs. NO-PRP group, 51.06
2vs. 31 6 1.5, p,0.05) (Figure 3C-D).
Effects of PRP on the post-injury expression pattern of
muscle-specific miRNAs involved in skeletal muscle
regeneration
At day 2 after injury, the expression level of miR-1, miR-133a
and miR-206 was significantly decreased, more than 0.5-fold with
respect to the pre-injured level (p,0.05), independently from the
presence or not of PRP (Figure 4A). At day 5, the expression level
of each miRNA in the NO-PRP group was increased, returning to
approximately the same level as that of pre-injury (p.0.05),
whereas in the PRP group only the miR-1 and miR-206 levels
were back to the Ctrl group magnitude (p.0.05). Differently,
miR-133a was still significantly lower when compared to both the
Ctrl and NO-PRP groups (p,0.05) (Figure 4B).
We then analyzed, under the same experimental condition, the
protein expression of SRF, the most reliable molecular target of
miR-133. Indeed, at day 2 SRF protein level was significantly
increased with respect to the Ctrl group (PRP, 2.52 6 0.29; NO-
PRP, 2.25 6 0.41, p,0.05), without differences between the two
experimental groups (p.0.05) (Figure 4C). At 5-day post-injury,
while in the PRP group the level of SRF was still significantly
higher than in the Ctrl group, in the NO-PRP group the level of
SRF protein returned to approximately the same level as in
uninjured group (PRP, 2.01 6 0.19, p,0.05; NO-PRP 1.26 6
0.28, p.0.05) (Figure 4C).
Analysis of p38MAPK, ERK and AKT activations in post-
injury muscle tissue treated or not with PRP
The evaluation of several signaling pathways, involved at
different times during muscle regeneration process, showed that
only ERK activation was modulated by the presence of PRP while
no effect on p38MAPK and AKT activation was observed
(Figure 5). As expected, a significant decrease in p38MAPK
phosphorylation at day 2 (Ctrl vs. 2d PRP vs.2d NO-PRP group,
3.32 6 0.28 vs. 1.79 6 0.09 vs. 1.05 6 0.18, p,0.05), followed by
Figure 1. Changes in the fold increase expression levels of (A) cytokines (TNFa, IL-6, IL-10, IL-1b, and TGF-1b) (B) myogenic response
factors (MyoD1, Myf5, Pax7, Myogenin and Mrf4) and (C) growth factors (VEGF-A and IGF-1Eb) mRNA in skeletal muscle treated or
not with PRP during the experimental period (at day 2 and 5). The y-axis for all graphs represents the fold-difference relative to the Ctrl
group. * represents significant difference between injured compared with the Ctrl group (p,0.05). 1 represents a significant difference between the
PRP-injury treated group and the NO PRP-injury treated group (p,0.05). Values are means 6 SEM (n= 5 rats/group at each time point). Dashed line
represents the base line control group.
doi:10.1371/journal.pone.0102993.g001
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Figure 2. Effects of PRP on total MyoD1 (A) and Myogenin (B) protein expression in uninjured skeletal muscle of rat (Ctrl), injured-
PRP treated (PRP group) or not PRP treated (NO-PRP group) at different times post-injury (at day 2 and 5). The relative protein
expression was determined by the ratio of the sample value to an internal standard control (GAPDH). Values are means 6 SEM (n=5 rats/group at
each time point). * represents a significant difference between injured groups and the Ctrl group (p,0.05). 1 represents a significant difference
between PRP-injury treated groups and NO PRP-injury treated groups (p,0.05).
doi:10.1371/journal.pone.0102993.g002
Figure 3. Immunohistochemical analysis of (A) MyoD1-positive or (C) Pax7-positive nuclei in skeletal muscle injury treated or not
with PRP. Representative double-immunoflorescence staining of skeletal muscle for (B) MyoD1 (green) and laminin (red) or (D) Pax7 (green) and
laminin (red), at day 2- and 5, respectively. Myonuclei were counterstained by blue fluorescent dyes (Hoechst). The percentage of MyoD1-positive or
Pax7-positive cells was calculated as the ratio of the number of nuclei in MyoD1- or Pax7 positive cells over that of Hoechst-positive nuclei. Results
were presented as means 6 SEM from n= 5 rats/group per time point and on five sections from each animal. Scale bars = 50 mm. * p,0.05 vs. Ctrl
group. 1p,0.05 vs. NO-PRP group.
doi:10.1371/journal.pone.0102993.g003
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a later recovery at day 5 (Ctrl vs. 5d PRP vs. 5d NO-PRP group,
3.32 6 0.28 vs. 2.75 6 0.44 vs. 2.37 6 0.06, p.0.05), was
observed with respect to the Ctrl group (Figure 5A). Differently,
the presence of PRP induced a higher rate of ERK1/2
phosphorylation both at 2- and 5-day post-injury (2d PRP vs. 2d
NO-PRP group, 2.826 0.19 vs. 1.97 6 0.17, p,0.05; 5d PRP vs.
5d NO-PRP group, 2.70 6 0.15 vs. 1.87 6 0.15, p,0.05)
(Figure 5B). Although we identified a great individual variability in
the expression of total AKT, with no statistical differences among
experimental groups (p.0.05), we did not find any appreciable
AKT phosphorylation, at any experimental time points and in the
groups analyzed (Figure 5C).
Effect of PRP treatment on the expression level of HSPs
and apoptotic markers following skeletal muscle injury
Changes in the mean protein expression levels of HSPs are
shown in Figure 6. The level of aB-crystallin protein in muscle
injured was greater than in the Ctrl group at 5-day post-injury,
independently from the presence of PRP (Ctrl vs. 5d PRP, 0.25 6
0.06 vs. 0.73 6 0.09; Ctrl vs. 5d NO-PRP group, 0.25 6 0.06 vs.
0.82 6 0.09, p,0.05) (Figure 6B), while the effect of PRP was
evident on the activation of this sHSP. Indeed, the level of
phospho-aB-crystallin observed in PRP group 5 days after PRP
application was 4 times greater than in NO-PRP group (Ctrl vs. 5d
PRP group, 0.32 6 0.28 vs. 2.28 6 0.07, p,0.05; 5d PRP group
vs. 5d NO-PRP group, 2.28 6 0.07 vs. 0.55 6 0.10, p,0.05)
(Figure 6C).
The level of Hsp27 protein in all injured groups and at both
sample timings was significantly higher when compared to the
uninjured group (Ctrl vs. 2d PRP group; 0.32 6 0.03 vs. 0.69 6
0.14, p,0.05; Ctrl vs. 2d NO-PRP group, 0.32 6 0.03 vs. 0.87 6
0.11, p,0.05; Ctrl vs. 5d PRP group, 0.326 0.03 vs. 1.406 0.28,
p,0.05; Ctrl vs. 5d NO-PRP group, 0.32 6 0.03 vs. 1.28 6 0.22,
p,0.05), independently from PRP treatment (Figure 6D). No
significant differences in Hsp27 protein phosphorylation among
groups were identified, even though an upward trend was
observed at day 5 in presence of PRP (Ctrl vs. 5d PRP group,
0.68 6 0.01 vs. 1.24 6 0.23, p= 0.061) (Figure 7E).
Figure 4. Real time-PCR analysis of miR-1, miR-133a and miR-206 expression using total RNA isolated from Ctrl-, PRP- and NO-PRP-
group at 2 (A) and 5 (B) day post-injury. C) Western blot analysis of SRF protein expression in skeletal muscle at 2- and 5-day post-injury. The
histograms represent fold change expression calculated as means 6 SEM (n= 5 rats/group at each time point) respect to the Ctrl group. *p,0.05 vs.
Ctrl group. 1p,0.05 vs. 5d NO-PRP group. Dashed line represents the base line Ctrl group.
doi:10.1371/journal.pone.0102993.g004
Figure 5. Effects of PRP on (A) p38MAPK, (B) ERK activity and (C) AKT tot at 2- and 5-day post-injury in regenerating skeletal
muscle. Bar diagrams representing the densitometric intensities of p-p38MAPK, pERK1/2 and AKT tot normalized with those for p38MAPK, ERK and
GAPDH content, respectively. Results were presented as means 6 SEM from n= 5 rats/group per time point. *p,0.05 vs. Ctrl group. 1p,0.05 vs. NO-
PRP group.
doi:10.1371/journal.pone.0102993.g005
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There was no significant difference in the expression level of
Hsp70 protein among all three groups analyzed (p.0.05)
(Figure 6F).
Our results also identified a significant increase of NF-kB-p65 at
2-day post-injury without any effect of PRP treatment (Ctrl vs. 2d
PRP, 0.09 6 0.02 vs. 0.65 6 0.12, p,0.05; Ctrl vs. 2d NO-PRP,
0.09 6 0.02 vs. 0.73 6 0.04, p,0.05). On the contrary, at 5-day
post-injury, while in PRP group the level of NF-kB-p65 was still
significantly higher than in the Ctrl group, in the NO-PRP group
the NF-kB-p65 protein returned to approximately the same level
as in the Ctrl group (5d PRP vs. 5d NO-PRP group, 0.95 6 0.13
vs. 0.29 6 0.09, p,0.05) (Figures 7A-B).
The analysis of apoptotic markers revealed that, in injured
muscles, although the Bax/Bcl-2 ratio was significantly increased
when compared to the Ctrl group without any modulation
induced by PRP (p,0.05) (Figures 7A-C), the level of cleaved-
caspase 3 was reduced at all time points in PRP-group (p,0.05)
(Figure 7A).
Discussion
The capacity of adult muscle tissue to regenerate in response to
injury represents an important homeostatic process. Despite major
advances in medicine, no optimal therapy has yet emerged, but
the need for evidence-based strategies to regenerate or at least
accelerate the regeneration of the muscle tissue still remains
considerable.
To our knowledge, this is the first report describing in detail
how the application of PRP to animal skeletal muscle injury can
modulate, at early stages, specific molecular pathways linked to the
muscle regeneration process. Indeed, we analysed multi-direction-
ally effects of PRP on skeletal muscle regeneration, including the
response of several MRFs, cytokines, GFs and micro-RNAs related
to myogenesis in vivo. We also considered the effects of PRP in
regulating stress response proteins, such as HSPs and apoptotic
markers, which play a part in the tightly regulated system for the
maintenance of myogenic cell homeostasis, as well as for their
survival and differentiation.
Skeletal muscle regeneration consists of two overlapping stages:
muscle fiber degradation, accompanied by an inflammatory
response, and a reconstruction phase, which starts with the
activation of muscle precursor cells, i.e. satellite cells, followed by
their proliferation and differentiation of satellite cells-derived
myoblasts into muscle fibers [16]. However, it must be considered
that the study of muscle regeneration progress in experimental
models might be influenced by the methods of injury (i.e.,
myotoxin, mechanical, etc.) as well as by the type of regenerating
muscle under analysis [17,18].
The early phase of muscle injury is usually accompanied by the
activation of inflammatory cells residing within the muscle, which
Figure 6. Effect of PRP treatment on several HSPs during regeneration process (2- and 5-day post-injury). (A) Representative
immunoblot of each protein marker reported. (B) aB-crystallin; (C) S59 phospho-aB-crystallin; (D) Hsp27; (E) S82 phpspho-Hsp27; (F) Hsp70. Each bar
represents mean value 6 SEM (n= 5/group at each point). * p,0.05 vs. Ctrl group.1 p,0.05 vs. 5d NO-PRP group.
doi:10.1371/journal.pone.0102993.g006
Figure 7. Effect of PRP treatment on several apoptotic markers during regeneration process (2- and 5-day postinjury). (A)
Representative immunoblot of each protein marker reported; (B) NF-kB-p65, and (C) Bax/Bcl-2 ratio. Values are means 6 SEM (n = 5/group at each
point). * p, 0.05 vs. Ctrl group.1 p, 0.05 vs. 5d NO-PRP group.
doi:10.1371/journal.pone.0102993.g007
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release pro- and anti-inflammatory cytokines such as TNFa, IL-6,
IL-10, IL-1b and TGF-b1. These cytokines play an important role
in cell proliferation, chemotaxis and cell differentiation. After
skeletal muscle injury, TNFa is released not only by infiltrating
macrophages, but also by injured muscle fibers [19]. Its expression
remains at high levels during the repair process and returns to
normal levels several days after the injury [20]. With similar time
course of expression, skeletal muscle produces IL-6 in response to
the injury, acting both as a factor for the proteolysis of damaged
myofibers and as a signal for satellite cell proliferation [20,21].
Although in our model we found a post-injury up-regulation of
TNFa, IL-6 and IL-10, a known cytoprotective cytokine that is
endogenously associated with improved muscle regeneration [22],
no differences were detected with respect to the utilization of PRP.
On the contrary, PRP treatment increased significantly the levels
of others early pro-inflammatory cytokines, IL-1b, and of TGF-b1,
a controversial secreted cytokine that, although known to be up-
regulated in response to injury [23], has been related to the
inhibition of myogenic differentiation and to the formation of
fibrosis following muscle injury [24,25]. Indeed, there is theoretical
deleterious side effect of PRP based on the elevation of TGF-b1
levels after its injection/application into muscle with possible
fibrotic healing response [26]. Therefore, since fibrotic healing
following muscular injury can lead to an increased incidence of re-
injury, it is important to advocate caution when considering PRP
injections in muscular injury. However, it should be taken into
consideration that in vivo studies demonstrate that TGF-b1 can
inhibit, induce or have no effect on satellite cells proliferation,
depending on the concomitant presence of other GFs [27,28].
Since analysis of the effect of PRP in the late stages of muscle
regeneration overcomes the aim of this study, we cannot expect
whether in this experimental conditions the gel application induces
a more helpful restoration of normal muscle tissue. Further studies
are needed to demonstrate if our preparation of PRP induces not
only a proper formation of muscle tissue but also a more rapid
recovery after injury.
Following the inflammatory response, activation of normally
quiescent satellite cells (SCs) is an integral part of the repair
process [29]. This process is characterized by an increased
transcription of the myogenic regulatory factors MyoD1, Pax7,
Myf5, myogenin and Mrf4 [30].
As expected, at day 2- and/or 5 early stages of muscle
regeneration, both mRNA transcripts for MyoD1, Myf5, Pax7,
myogenin and an abundant number of MyoD1- and Pax7-positive
cells were present in all experimental groups after muscle injury,
but this response was clearly more elevated in the muscle treated
with PRP, with the exception of Mrf4 mRNA and myogenin
protein levels. We were not surprised to find no modulation of
Mrf4 myogenic factor at the stages of regeneration selected in this
study, since Mrf4 expression has been reported in the later stages
of regeneration [31]. The same could also to be true for the
myogenin protein level, where the lack of protein modulation may
depend on the early observation window selected.
From our data, we can then hypothesize that PRP produced a
major effect on muscle regeneration both through the up-
regulation of Pax7 and Myf5, which leads to an increase in
myogenic precursor cells and through an increase in MyoD1
expression, which is consistent with an expansion of the myogenic
cell pool necessary for myofiber formation.
Collectively, these findings, together with those recently
reported [6,7], demonstrate that following a muscle injury, PRP
treatment induces a marked expression of pro-inflammatory
cytokines, amplifying the physiological early inflammatory re-
sponse by modification of the recruitment pattern of immune cells,
as well as the enhanced expression of myogenic factors, able to
increase myogenesis.
Recent studies highlight the possibility that VEGF’s ability to
promote vascularization could increase the availability of blood
vessel–associated stem cells capable of participating in muscle
regeneration [32]. However, a direct improvement in muscle
regeneration has not been documented. We have recently
reported the absence of significant differences in both blood vessel
density and diameter among PRP-treated and untreated groups
[7]. Similarly, in the present study, where the same injury model
was used, we did not find any specific induction of VEGF after the
muscle injury, irrespective of the presence or not of PRP.
On the contrary, following imposed local damage, we found an
early and huge increase of IGF-1Eb mRNA, with a clear
enhanced effect induced by PRP application. It is known that
IGF-1Eb acts as a survival factor by prolonging the regenerative
potential of skeletal muscle not only through an increase in satellite
cell activity but also establishing a balance between inflammation
and connective remodeling [33–35]. Although defined signaling
pathways, both upstream and downstream of IGF-1Eb, are still
being studied, recent results suggest that IGF-1Eb is responsible
for muscle progenitor cell proliferation through ERK activation
but not through AKT [36,37]. It is interesting to note that,
concomitant with the up-regulation of IGF-1Eb, we found a
marked phosphorylation of ERK1/2, while, despite the individual
variability of AKT’s expression, its phosphorylated form has never
been detected.
These findings suggest that the increased expression of IGF-1Eb
and the activation of ERK, leading to a higher proliferation rate of
muscle progenitor cells, could represent an important molecular
step for the effect of PRP during the early stages of muscle
regeneration.
Growing evidences demonstrate that muscle specific miRNAs,
also defined myomiRs, function as a control center in directing
diverse biological processes during myogenic proliferation and
differentiation [38]. Of these, the most widely studied are
members of miR1, miR206 and miR-133 families [39,40].
It is known that miR-1 promotes myogenesis by targeting
histone deacetylase 4 (HDAC4), a transcriptional repressor of
muscle gene expression, while miR-206 promotes muscle differ-
entiation as well as improves skeletal muscle hypertrophy and
regeneration by repressing the expression of connexin 43 (Cx43),
follistatin-like 1 (Fstl1) and utrophin (Utrn) [41–45]. Differently, it
remains controversial whether miR-133 promotes or inhibits
muscle cell proliferation [40,46,47]. To understand if the presence
of PRP was potentially able to modulate the expression of
miRNAs, we analyzed the expression of miR1, miR206 and miR-
133a during the early stages of skeletal muscle regeneration.
Several groups have already shown that the expression levels of
these miRNAs decreased subsequent to injury, thereafter their
levels gradually returned to pre-injury level during the regener-
ation process [47–50]. In agreement with those data, our results
showed that the level of miR-1, miR-206 and miR-133a decreased
at day 2 after muscle injury in all experimental groups, returning
to pre-injury levels at day 5, with the exception of miR133a, which
still remained down-regulated in the presence of PRP. Among the
possible targets of miR133, the most reliable is the serum response
factor (SRF), which plays a critical role in muscle proliferation and
differentiation depending on its association with co-factors such as
myocardin, HOP, and Elk-1 [40,47,51–53].
The expression pattern of SRF observed in the present study
seems to support the hypothesis of a specific effect of PRP on miR-
133 function. Indeed, an inverse correlation between the
expression levels of SRF and miR-133 was observed at least at
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5-day post injury when comparing PRP versus NO-PRP or Ctrl
samples. Although the differences in protein levels of SFR between
PRP and NO-PRP groups were not statistically significant, the
reduced content observed in NO-PRPs could still be relevant.
Moreover the SRF amount in the Ctrl group, which is similar to
that of NO-PRPs, was significantly lower than in the PRP group.
Since is known that a high expression of miR-133 as well as a SRF
reduction repress the expression of MyoD, myogenin and MyHC
[40,54], our results leave us to believe that PRP could be
remarkably effective in promoting muscle regeneration by a
molecular regulatory mechanism involving also miR-133-mediat-
ed up-regulation of SRF expression levels (Figure 8).
Activation of p38MAPK is a key signaling step involved in the
myogenic differentiation [47,55,56]. Our analysis showed atten-
uated expression of its phosphorylated form at early stages of
muscle regeneration. Besides to support the hypothesis that p38
signaling might be one of the upstream signaling regulating
myomiRNAs, it is interesting to note that p38MAPK modulation
was concomitant with the down-regulation of all selected
myomiRNAs. As already suggested by Zhang et al (2012) [47],
this phenomenon could facilitate myoblast proliferation resulting
in an increased number of myoblasts ready for differentiation.
Further, since it has been shown that constitutive activation of
p38MAPK induce interstitial fibrosis [57,58], its early decrease
may protect skeletal muscle against fibrosis. This observation gains
even more strength when considering PRP clinical application
since muscle fibrosis may lead to an increased risk of re-injury.
Increased HSPs expression has been described during periods
associated with enhanced protein synthesis, protein degradation
and cellular reorganization, such as muscle regeneration [59]. This
is especially true for two specific small heat shock proteins also
defined as muscle-specific HSPs [60], Hsp27 and aB-crystallin,
whose regulation is important for their role in structural cellular
maintenance and molecular chaperone in myofiber stabilization
[61-63] as well as in the resistance to apoptosis conferred during
muscle differentiation [64–67]. It is also reported that the
phosphorylation pattern of these sHSPs changes during differen-
tiation modifying their activity, localization and interaction with
other proteins and cellular functions [68–70].
In particular, aB-crystallin and its phosphorylated form increase
NF-kB activity, whose target genes regulate biological process such
as growth, differentiation and cell survival [71,72].
In agreement with previous study [73], we found that during
muscle regeneration the expression levels of both Hsp27 and aB-
crystallin increased without a significant modification of Hsp70.
Moreover, only in the presence of PRP we found a significant
increase of phospho-aB-crystallin at 5-day post-injury.
Since a recent study showed that the up-regulation of Hsp70 is
indeed important for muscle regeneration through regulating both
the early inflammatory and regenerative phases following muscle
injury [74], we cannot exclude that its over-expression was earlier
than our observation point at day 2. However, the above cited
conclusion was derived from data obtained using the cardiotoxin
model of muscle injury which usually results in a high level of
myofibers necrosis (greater than 90%) [75]. Therefore, the
activation of all cellular pathways in cardiotoxin-injured muscles
may be considerably different and/or more important than in
more physiological forms of muscle injury.
It is interesting to note that the ratio Bax/Bcl-2 was not different
in presence or not of PRP, however, the expression of NF-kB p65
Figure 8. Model of PRP-mediated regulation of skeletal muscle healing. The presence of PRP modulated the expression of miR-133a and
SRF protein as well as several myogenic response factors such as MyoD1, Pax7, and Myf5, the growth factor IGF-1Eb and both the cytokine IL-1b and
TGF-1b. The modulation of these factors may affect important physiological processes such as the inflammatory response, myoblast proliferation and
differentiation, production of extracellular matrix, and myoblast apoptosis.
doi:10.1371/journal.pone.0102993.g008
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was higher where the lesion was treated with PRP with the
concomitant reduction in the amount of cleaved caspase 3. As
already hypothesized by other authors [76,77], even under these
stress conditions, we can image a similar mechanism by which
Hsp27, aB-crystallin and its phosphorylated form inhibit apopto-
sis. Following muscle injury, serine-59 is phosphorylated causing a
translocation of aB-crystallin to the myofilaments and nucleus
where it binds titin, desmin, vimentin, nebulette, and inactive
precursor of caspase 3, leading to the stabilization of the
myofilament and to the inhibition of apoptosis [76,77]. Although
also not phosphorylated aB-crystallin is still capable to activate
NF-kB, its phosphorylated form enhances even more NF-kB
activity, conferring increased protection to the cells during
regeneration process [77] (Figure 9).
Conclusion
Application of PRP for musculoskeletal injuries is relatively new,
and although its injections resulted in improved function,
diminished pain and swelling with a shorter time of restoration
and rehabilitation [14,78-80], a number of important questions
when considering its efficacy, safety as well as the ideal PRP
formulation and frequency of injections/applications, require
appropriate scientific investigation. Currently, the majority of
human clinical studies show good results treating tissue pathology
with one PRP injection/application [81-87], while in case of
others a higher number was needed [5,88–92].
As already hypothesized [6,90,93], the variability observed in
PRP response profiles may be explained by the different
anatomical and physiological characteristics of tissues analysed,
as though the type of tissue and grade of tissue pathology heal with
a different PRP request. Nevertheless, all studies above cited
report an enhanced healing and functional recovery, reduced pain
and increased function, no wound complications and no adverse
events.
PRP has been demonstrated for over 20 years to be a safe and
effective treatment option in both human and animal studies; its
autologous nature eliminates any concerns of immunogenic
reactions or disease transfer [94]. No studies have documented
that PRP promotes hyperplasia, carcinogenesis, or tumor growth.
Relative contraindications include the presence of a tumor,
metastatic disease, active infections, low platelet count, pregnancy
or active breastfeeding [95]. Further, although the formal etiology
remains unclear, Kaux and collegues [96] reported an adverse
reaction after a local injection of PRP in type 1 diabetes patient.
Thus, the balance between the benefits and the risks must be
carefully evaluated before using this treatment in patients with
type 1 diabetes.
We must always keep in mind that PRP should not be thought
as a benign ‘‘physiological’’ substance but rather a manipulated
and ‘‘supraphysiological’’ product with properties potentially quite
distinct from its original state.
Nevertheless, based on our observations we strongly believe that
this study, together with already published results [5–7,14,97], are
making significant progress towards establishing full signaling
pathway induced by PRP during muscle regeneration. Indeed, the
present study also demonstrated a modulation of the inflammatory
response, which may explain the pain reduction usually observed
after PRP administration and account for the early mobilization of
treated patients [98-99], it showed how PRP produces a more
pronounced increase of myogenic precursor cells together with an
expansion of the myogenic cell pool necessary for myofiber
formation. Moreover, it demonstrated that PRP is able to
modulate positively even the expression of stress response proteins,
directly or indirectly correlated with the regeneration process.
However, this study still has several limitations. The first and most
obvious is that findings from animal studies are not always
applicable to humans. Second, even though the macroscopic
observation allowed us to establish the timing of muscle recovery
following the lesion [7], we did not analyze neither the PRP’s effect
on functional recovery nor the force of contraction beyond
selected experimental points. Moreover, it would be interesting to
perform an ultrasonography analysis in order to illustrate the
enhanced regeneration in the absence of fibrosis.
Therefore, before a clinical trial can be carried out, additional
studies are essential to demonstrate the efficacy and safety of PRP
application as well as the possible combined/synergic effect of
PRP with specific training protocol, such as the eccentric physical
therapy [100]. If elucidated, this concept of mechanical stimula-
tion after PRP treatment could be beneficial to human soft tissue
Figure 9. Schematic representation of the role of aB-crystallin and Hsp27 in the myofiber stabilization and in cytoprotection
following skeletal muscle injury. The presence of PRP enhances phosphorylation of Ser-59 of aB-crystallin, which binds myofilaments and the
inactive precursor of caspase 3, causing their stabilization and inhibition of apoptosis. Further, phospho Ser-59 aB-crystallin enhances NF-kB-p65
activation which may contribute to increased cell survival during regeneration process.
doi:10.1371/journal.pone.0102993.g009
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and other pathologies that are sensitive to variation in local tissue
strength.
Supporting Information
Figure S1 Surgical and delivery procedure of platelet
gel in injured muscle. A) Withdrawal of intracardiac blood; B)
Transfer blood into vacutainer tubes with sodium citrate for
centrifugation steps; C) Multiwell with platelet gel; D) Incision
upper limb; E) Identification upper limb flexor muscle; F) Platelet
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